EUVIMEDEUVIMED entdecken
Open Access

Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non–Small Cell Lung Cancer

Jeanna Wallenta Law iD, Bela Bapat, Connor Sweetnam iD, Hina Mohammed iD, Ashleigh McBratney iD, Monika A Izano iD, Molly Scannell Bryan iD, Scott Spencer, Brock Schroeder, Damon Hostin, George R Simon iD, Anna B Berry iD

JCO Precision Oncology · 2024-05 · (8)

DOI: 10.1200/po.24.00075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024-05. Verfasst von Jeanna Wallenta Law und 11 weiteren Autor:innen. Beteiligte Einrichtung: Syapse Holdings Inc, West Chester, PA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Therapeutic decision making for patients with advanced non–small cell lung cancer (aNSCLC) includes a growing number of options for genomic, biomarker-guided, targeted therapies. We compared actionable biomarker detection, targeted therapy receipt, and real-world overall survival (rwOS) in patients with aNSCLC tested with comprehensive genomic profiling (CGP) versus small panel testing (SP) in real-world community health systems. METHODS Patients older than 18 years diagnosed with aNSCLC between January 1, 2015, and December 31, 2020, who received biomarker testing were followed until death or study end (September 30, 2021), and categorized by most comprehensive testing during follow-up: SP (≤52 genes) or CGP (>52 genes). RESULTS Among 3,884 patients (median age, 68 years; 50% female; 73% non-Hispanic White), 20% received CGP and 80% SP. The proportion of patients with ≥one actionable biomarker (actionability) was significantly higher in CGP than in SP (32% v 14%; P < .001). Of patients with actionability, 43% (CGP) and 38% (SP) received matched therapies ( P = .20). Among treated patients, CGP before first-line treatment was associated with higher likelihood of matched therapy in any line (odds ratio, 3.2 [95% CI, 1.84 to 5.53]). CGP testing (hazard ratio [HR], 0.80 [95% CI, 0.72 to 0.89]) and actionability (HR, 0.84 [95% CI, 0.77 to 0.91]) were associated with reduced risk of mortality. Among treated patients with actionability, matched therapy receipt showed improved median rwOS in months in CGP (34 [95% CI, 21 to 49] matched v 14 [95% CI, 10 to 18] unmatched) and SP (27 [95% CI, 21 to 43] matched v 10 [95% CI, 8 to 14] unmatched). CONCLUSION Patients who received CGP had improved detection of actionable biomarkers and greater use of matched therapies, both of which were associated with significant increases in survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorHumansFemaleMaleAgedMiddle AgedGenomicsAged, 80 and overTreatment Outcome

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Syapse Holdings Inc, West Chester, PA.
  • Illumina, San Diego, CA.
  • Moffitt Cancer Center, Tampa, FL.

ORCID-Profile: Jeanna Wallenta Law, Connor Sweetnam, Hina Mohammed, Ashleigh McBratney, Monika A Izano, Molly Scannell Bryan, George R Simon, Anna B Berry

Zitieren

APA

Wallenta Law, J., Bapat, B., Sweetnam, C., Mohammed, H., McBratney, A., Izano, M. A., Scannell Bryan, M., Spencer, S., Schroeder, B., Hostin, D., Simon, G. R., & Berry, A. B. (2024). Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non–Small Cell Lung Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.24.00075

Vancouver

Wallenta Law J, Bapat B, Sweetnam C, Mohammed H, McBratney A, Izano MA, et al. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non–Small Cell Lung Cancer. JCO Precision Oncology. 2024. doi:10.1200/po.24.00075

BibTeX
@article{WallentaLaw2024,
  author = {Wallenta Law, Jeanna and Bapat, Bela and Sweetnam, Connor and Mohammed, Hina and McBratney, Ashleigh and Izano, Monika A and Scannell Bryan, Molly and Spencer, Scott and Schroeder, Brock and Hostin, Damon and Simon, George R and Berry, Anna B},
  title = {Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non–Small Cell Lung Cancer},
  journal = {JCO Precision Oncology},
  year = {2024},
  number = {8},
  doi = {10.1200/po.24.00075}
}
Kostenlos starten →